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R E V I E W A R T I C L E
Neuronal surface 
autoantibodies, encephalitis, 
and psychosis: from neurology 
to psychiatry
Autoimmune encephalitis in the 2000s
It has been over a decade since the first description of an encephalitis presenting 
with psychosis, occurring in young women with ovarian teratoma.1 This disorder, 
now known to be caused by autoantibodies which recognise the NR1 subunit of the 
N-methyl-D-aspartate (NMDA) receptor (NMDAR), has had a profound effect on the 
neurological landscape. NMDAR-antibody encephalitis has also had an effect on the 
cultural landscape, with Susannah Cahalan’s bestselling account of her experience of 
the disorder, Brain on Fire, topping the New York Times bestseller list and being made 
into a Hollywood movie. 
But why was the impact of this newly described disorder so great? After all, it was in 
the 1960s that Brierley, Corsellis and colleagues first penned their seminal descriptions of 
limbic encephalitis. All of the original case descriptions, like Cahalan herself, presented 
with psychiatric symptoms before going on to develop various neurological symptoms 
including seizures and cognitive dysfunction.2 
Unlike these original cases, however, NMDAR-antibody encephalitis is highly responsive 
to immunotherapy.  We now know that this is because NMDAR antibodies attach to the 
neuronal surface (unlike the classical ‘onconeural’ antibodies associated with paran-
eoplastic limbic encephalitis) and are therefore accessible in vivo to antibody-directed 
immunomodulatory therapies. This was not a novel paradigm as such, having been well 
established in myaesthenia gravis. However, this disorder was occurring within the central 
nervous system, thereby challenging the notion that antibodies or antibody-secreting cells 
could not cross the blood brain barrier and that the brain was an immune privileged site.
Further, as the number of reported cases began to increase, it became apparent that 
a minority of patients presented solely with psychiatric symptoms throughout the course 
of their illness.3 What was novel was not the fact that CNS inflammation can cause an 
immunotherapy-responsive isolated psychiatric phenotype – indeed, neurologists have 
been treating psychosis due to SLE and other CNS inflammatory disorders for years, despite 
little understanding of the mechanisms underlying psychotic symptoms in these disorders. 
The real breakthrough lies in the fact that a relatively straightforward laboratory test has 
enabled the identification of an entirely new repertoire of neuronal autoantibodies that 
target relatively well-characterised membrane proteins involved in neurotransmission, 
offering a mechanistically plausible pathway from antigen to symptoms and indeed to 
psychopathology.4 In 2017, many of these novel autoimmune encephalitides – associated 
with antibodies targeting the AMPA, glycine, GABA-A and –B receptors or other membrane 
proteins such as leucine-rich glioma inactivated 1 (LGI1) and contactin-associated protein-
like 2 (CASPR2) – are now familiar to most UK neurologists. New antigenic targets – mostly 
extracellular, although occasionally intracellular/cytosolic – are being reported every few 
months (IgLON5, dipeptidyl-peptidase-like protein-6 [DPPX], and neurexin 3_ encephal-
itis have all been described in the last few years)5 (see Table 1). Unlike with syndromes 
associated with the classical onconeural antibodies, only a minority of patients have an 
associated tumour, such as an ovarian teratoma in NMDAR-antibody encephalitis; if a 
tumour is present, resection appears to expedite recovery.
The technology that has enabled this explosion of discovery of immunotherapy-re-
sponsive disease in an ever-growing number of patients is the development of cell-based 
assays (CBAs) for the detection of neuronal surface autoantibodies. CBAs are cell lines, 
transfected with a genetic construct containing the target antigen of interest. This leads to 
surface expression of the antigen, thereby avoiding exposure of pathogenically irrelevant 
intracellular epitopes and also maintaining the native conformation of the target protein. 
This is a crucial feature of this group of antibodies to which previous detection methods 
such as ELISAs and western blots are largely insensitive.
The impact on psychiatry
If the impact on neurology has been great, the impact on psychiatry has been no less 
profound. Of the original 100 cases of NMDAR encephalitis described by Dalmau and 
colleagues, 77% presented to psychiatric services, the majority with largely psychotic 
symptoms.6 That proportion is perhaps smaller in the UK today, partly due to greater 
awareness amongst clinicians, but the fact remains that in its early stages, autoimmune 
encephalitis can be a mimic of first episode psychosis (FEP). 
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Antigen Antigen description/epitope Main encephalopathy syndrome; which possible psychiatric 
features?
Other associated neurological 
disorders
NMDAR  
(NR1 subunit)
Ligand gated ion channel subunit Encephalopathy (usually extralimbic).
Psychiatric features include anxiety, agitation, bizarre 
behaviour, catatonia, delusional or paranoid thoughts, and 
visual or auditory hallucinations. Also movement disorder, 
seizures, autonomic instability.3,24,25
Post-herpes simplex encephalitis 
relapse with chorea; idiopathic 
epilepsy; immunotherapy-responsive 
dementia.26,27
LGI1 VGKC- and AMPAR-associated 
secreted molecule
LE with or without faciobrachial dystonic seizures (FBDS).
Psychiatric features include confusion, hallucinations, 
depression.28
Morvan’s syndrome, NMT, epilepsy, 
REM sleep behaviour disorder28
CASPR2 VGKC-associated adhesion molecule LE and Morvan’s syndrome.
Psychiatric features include confusion, hallucinations, 
agitation, delusions.29
NMT, epilepsy28
AMPAR Ligand gated ion channel LE. 
Psychiatric features include confusion, personality change, 
psychosis, apathy, agitation, confabulation. 30-32
GABAAR Ligand gated ion channel LE with refractory seizures. 
Psychiatric features include confusion, affective changes (inc 
depression), hallucinations33
Varied presentations.34
GABABR Ligand gated ion channel LE with refractory status epilepticus. 
Psychiatric features include psychosis, agitation, 
catatonia.30,35
Opsoclonus-myoclonus; cerebellar 
ataxia; PERM35,36
D2R Metabotropic receptor ‘Basal ganglia encephalitis’ with prominent movement 
disorder (dystonia, parkinsonism, chorea, tics).
Psychiatric features include agitation, depression, psychosis, 
emotional lability.
SC, PANDAS37
DPPX Auxiliary subunit of Kv4.2 potassium 
channels
LE with enteropathy. 
Psychiatric features include amnesia, delirium, psychosis, 
depression38,39
PERM40
MGluR5 Metabotropic receptor ‘Ophelia syndrome’: LE in association with Hodgkin 
lymphoma. One case of LE without lymphoma.
Psychiatric features include depression, anxiety, delusions, 
visual and auditory hallucinations, anterograde amnesia.41
IgLON5 Neural cell adhesion molecule of 
unclear function
Characteristic sleep disorder preceded or accompanied by 
bulbar symptoms, gait abnormalities, oculomotor problems 
and cognitive decline; a tauopathy, strongly associated with 
HLA-DRB1*10:01.42,43
Neurexin 3_ Synaptic molecule involved in 
formation and maturation of 
synapses
Infectious prodrome followed by cognitive dysfunction, 
seizures, reduced consciousness, and orofacial dyskinesias; 
sometimes severe clinical course; mimic of NMDARE but 
with less prominent psychiatric symptoms.44
ARHGAP26 A multidomain protein involved in 
regulation of endocytosis
Autoimmune cerebellar ataxia with dizziness and dysarthria; 
also memory dysfunction and depression.45,46
One patient reported with 
immunotherapy-responsive 
psychosis with suicidality, 
aggression, mutism.47
Synapsin A synaptic vesicle-associated 
protein involved in regulation of 
neurotransmitter release.
69-year-old man with confusion, disorientation, seizures, 
and left hippocampal hyperintensities on MRI.48
Synapsin IgG also found in patients 
with neurological and psychiatric 
disorders (including psychosis, 
depression and bipolar disorder).49 
AK5 An intracellular (cytosolic) 
nucleoside monophosphate kinase, 
expressed exclusively in the brain.
>50 yo; subacute pure anterograde amnesia, occurring in 
most cases after a prodromal phase of asthenia, anorexia, 
and depression. Hippocampal atrophy on MRI. Prominent 
anxiety, but seizures not reported.50
GFAP An intracellular (cytosolic) glial 
intermediate filament protein.
Corticosteroid-responsive meningoencephalitis or 
encephalitis, with or without myelitis. Presents with 
subacute onset of memory loss and confusion. Co-occurs 
with autoimmune endocrinopathy in one third, and with 
tumour in one third. Psychiatric symptoms reported in 
29%.51,52
adenylate kinase 5; ARHGAP26: Rho GTPase activating protein 26; ATD: amino terminal domain; BPAD: bipolar affective disorder; CBA: cell-based 
assay; ELISA: enzyme-linked immunosorbent assay; GFAP: glial fibrillary acidic protein; LE: limbic encephalitis; MDD: major depressive disorder; NMT: 
neuromyotonia; PERM: progressive encephalomyelitis with rigidity and myoclonus; RIA: radioimmunoassay; SC: Sydenham’s chorea; PANDAS: paediatric 
autoimmune neuropsychiatric disorders associated with Streptococcal infections. Table reproduced and updated with permission from Pollak et al. 4
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Similarities between NMDAR-antibody enceph-
alitis and psychosis are not limited simply to delu-
sions and hallucinations. Patients with psychotic 
disorders, even if antipsychotic-naïve, can present 
with catatonia, autonomic instability including 
hyperthermia, extrapyramidal signs including 
tremors and dyskinesias, hypersomnolence or 
acute insomnia, hyponatremia and even a delir-
ium-like picture.7 
In Brain on Fire, Cahalan is initially diagnosed 
with schizoaffective disorder by a psychiatrist, 
before she develops a frank encephalopathy and 
NMDAR-antibody encephalitis is diagnosed by her 
neurologist, Dr Najjar. Musing on her diagnostic 
journey, she asks a simple question: “how many 
people currently are in psychiatric wards and 
nursing homes denied the relatively simple cure 
of steroids, plasma exchange, [or] more intense 
immunotherapy…?”. Cahalan was not alone in 
wondering whether encephalitis was just the tip 
of the autoimmune iceberg. By 2011, psychia-
trists had begun to search for NMDAR and other 
neuronal surface autoantibodies in patients with 
so-called ‘primary’ psychotic disorders – those 
in which causation is thought to be complex or 
unknown.  The first study to look for these anti-
bodies in FEP found NMDAR and voltage-gated 
potassium channel complex antibodies in 7% of 
patients presenting to a community psychosis 
service in Cambridge. Importantly, one NMDAR 
autoantibody-positive patient was given plasmaph-
eresis and made a full psychiatric recovery that 
was sustained at seven months follow-up.8 
Reports of brain-reactive antibodies in psych-
osis are nothing new, dating back as far as the 
1930s, but in looking for antibodies strongly 
suspected to be pathogenic by virtue of their 
role in the various newly-described autoimmune 
encephalitides, the argument for plausible 
antibody pathogenicity in psychotic disor-
ders is strengthened. Most recently, Lennox 
and colleagues conducted the largest ever 
prospective study of neuronal surface autoanti-
bodies (NMDAR, LGI1, CASPR2, GABA-AR) in first 
episode psychosis, involving 230 young people 
from 14 sites around the UK. We found that 8% 
of subjects had a neuronal surface autoantibody 
detectable in peripheral blood, and for NMDAR-
antibodies the difference versus healthy control 
prevalence was statistically significant. Crucially, 
seropositive subjects were not distinguishable 
from seronegative subjects on the basis of clinical 
features alone.9 
Other recent studies, using various assays and 
confirmatory testing methods, have identified 
potentially disease-relevant antibodies in patients 
with a variety of psychosis diagnoses, including 
chronic psychosis,10 childhood-onset psychosis,11 
and postpartum psychosis.12 
For psychiatrists, these developments are 
exciting and parallel similar discussions in neur-
ology regarding the relevance of these antibodies 
in epilepsy, movement disorders and memory 
syndromes. They come at a time when psychiatry 
is increasingly looking towards neuro-immune 
interaction as a putative disease mechanism 
in psychotic and other severe mental illnesses. 
Genome-wide association studies suggest 
immune-related SNPs confer schizophrenia risk, 
raised inflammatory markers appear to char-
acterise acute illness stages, and considerable 
epidemiological overlap with autoimmune disor-
ders is attracting attention.13 For decades, there 
has been little progress in the pharmacological 
treatment of psychosis, and we still largely rely 
on dopamine D2 receptor antagonism, which is 
the same mechanism of action as that of chlor-
promazine, introduced in 1952. The possibility 
that even a subset of patients with psychosis may 
have an immunotherapy-responsive autoimmune 
basis to their disorder has therefore attracted 
considerable enthusiasm. 
But is this enthusiasm premature? So far, 
there have been numerous case reports of good 
immunotherapy-responses in patients with psych-
osis, and the largest open-label case series to 
date demonstrated improvement in symptoms 
concomitant with reduction in antibody titre 
in each of 9 patients with acute psychosis and 
NMDAR antibodies who received immuno-
therapy.14 But selection bias, placebo response 
to a dramatic, highly medicalised intervention, 
and regression to the mean cannot be ignored as 
potential factors here.
Current controversies
Biological psychiatry is replete with false dawns, 
and some authors are sceptical of the relevance 
of neuronal autoantibodies in psychotic disor-
ders.15 Critical debate tends to centre around two 
themes:
1) Serum neuronal surface autoantibodies are 
sometimes found in healthy people and in 
other, non-encephalitis diseases – therefore 
they can only have disease-relevance when 
there is a phenotype typical of classic descrip-
tions of autoimmune encephalopathies.
2) Serum antibodies without associated detect-
able CSF antibodies are unlikely to represent 
an antibody-mediated brain disease.
There continues to be active discussion around 
these points which cannot be adequately 
summarised here, but the following comments 
point towards some relevant considerations:
1) Different CBAs appear to have different sensi-
tivities and specificities. One theoretical factor 
contributing to this variation is that the fixa-
tion process may affect protein structure and 
permeabilisation may expose intracellular 
antigens allowing antibodies to bind that have 
a lower chance of pathogenic potential. One 
recent study in a first episode psychosis cohort 
demonstrated that live CBAs are more sensitive 
than fixed CBAs. Furthermore, single molecule 
imaging demonstrated to a high degree of like-
lihood that that even antibodies from weakly 
positive sera, far from being ‘false positive’, 
targeted the NMDAR.16
2) Whereas CSF antibodies, and evidence of 
intrathecal synthesis are frequently observed 
in typical NMDAR-antibody encephalitis, CSF 
positivity rates are much lower in other types, 
such as LGI1 or CASPR2-antibody encephal-
itis.17 Further, in animal models it has been 
demonstrated that at relatively low titres the 
brain can act as an ‘immunoprecipitator’ of 
NMDAR antibodies (and by extension presum-
ably other neuronal surface autoantibodies) 
meaning that unless the brain becomes satur-
ated due to an excess of antibody, as may be 
the case when there is intrathecal synthesis 
and active, florid encephalitis, absence of 
detectable CSF antibody does not necessarily 
exclude a CNS-binding surface antibody.18 
Indeed, cases of seropositive but CSF-negative 
NMDAR encephalitis have been reported 
using a live CBA in the UK.19 
Ultimately, despite these important scientific ques-
tions, as more patients are tested for these anti-
bodies clinicians need a clearer evidence base 
regarding treatment decisions. A placebo-con-
trolled double blinded randomised controlled 
trial, currently recruiting in the UK will help. The 
SINAPPS2 trial will randomise 80 patients with 
acute psychosis and neuronal surface autoanti-
bodies to receive either active immunotherapy 
(IVIG and rituximab) or sham immunotherapy in 
addition to psychiatric treatment as usual [clinic-
altrials.gov NCT03194815 / www.sinapps.org.uk].
Clinical best practice
Until the results of this RCT are known, which 
patients should be tested and what should neur-
ologists make of a positive neuronal surface 
autoantibody test in a patient whose symptoms 
are largely, or indeed wholly, psychiatric in 
nature? Crucially, one would not wish to miss 
making a diagnosis of autoimmune encephalitis 
as soon as possible, and potentially allowing 
intervention before the disease progresses to a 
more florid neurological picture. ‘Red flag’ signs, 
then, are those which suggest a greater or lesser 
degree of encephalopathy:7,20
- Acute/subacute onset
- Autonomic instability
- Language disorder
- Impairment of consciousness
- Significant cognitive dysfunction
- Seizures
- Neuroleptic sensitivity
Patients with a positive serum autoantibody test 
should be investigated with EEG, MRI and CSF 
analysis and diagnosis of autoimmune enceph-
alitis made with current guidelines in mind.21 
Where appropriate, the possibility of co-occurring 
tumour should be excluded. Ideally care should 
be shared between neurology and psychiatry; 
indeed throughout the UK, these disorders have 
heralded the development of innovative models 
co-working between neurology and psychiatry, 
both in inpatient and an outpatient settings.
In terms of psychiatric treatment, there is 
mounting evidence that patients with NMDAR-
antibody encephalitis may respond poorly 
to antipsychotic treatment, with high rates of 
rhabdomyolysis and even development of a 
neuroleptic malignant syndrome (NMS)-type 
picture.22,23 For this reason, benzodiazepines are 
preferred for initial management of behavioural 
disturbance and catatonia. If antipsychotics are 
required, sedating atypical antipsychotics such 
as olanzapine may be preferable.
With a considerable research effort now 
ongoing at an epidemiological, mechanistic, 
clinical and trial level, the identification of neur-
onal surface autoantibodies has re-energised 
biological psychiatry, suggesting new aetio-
logical insights, and potentially offering new 
treatment avenues for a group of disorders 
affecting millions worldwide.
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